Cyclosporine 5 mg/kg bid days 0-14 ( DrugBank: Cyclosporine )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
38	スティーヴンス・ジョンソン症候群	1
39	中毒性表皮壊死症	1

38. スティーヴンス・ジョンソン症候群

---

臨床試験数 : 17 /  薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	March 15, 2023	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States

39. 中毒性表皮壊死症

---

臨床試験数 : 13 /  薬物数 : 19 - (DrugBank : 8) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	March 15, 2023	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States